Delayed-onset heparin-induced thrombocytopenia and thrombosis

Annals of Internal Medicine

Volumn 135, Issue 7, 2001, Pages 502-506

  Warkentin, T E ^a   Kelton, J G ^a  

^a HAMILTON REGIONAL LABORATORY MEDICINE PROGRAM   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; IMMUNOGLOBULIN G ANTIBODY; SEROTONIN; THROMBOCYTE FACTOR 4;

AGED; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COMPLEX FORMATION; CONTROLLED STUDY; DELAYED ONSET HEPARIN INDUCED THROMBOCYTOPENIA; DISEASE COURSE; DRUG WITHDRAWAL; FEMALE; HEPARINIZATION; HUMAN; HUMAN CELL; MALE; PATHOGENESIS; PRIORITY JOURNAL; SERODIAGNOSIS; SEROTONIN RELEASE; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS;

EID: 0035797925     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-135-7-200110020-00009     Document Type: Article

References (20)

1. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin
2. Clinical picture of heparin-induced thrombocytopenia
3. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia
4. Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia
5. The epitope specificity of heparin-induced thrombocytopenia
6. Impact of the patient population on the risk for heparin-induced thrombocytopenia
7. Heparin-induced thrombocytopenia with associated disseminated intravascular coagulation
8. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia
9. Heparin-induced thrombocytopenia with thromboembolic complications: Meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range
10. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia
11. Generation of platelet-derived microparticles and procoagulant activity by heparin-induced thrombocytopenia IgG/serum and other IgG platelet agonists: A comparison with standard platelet agonists
12. Morphological analysis of microparticle generation in heparininduced thrombocytopenia
13. Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia
14. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells
15. Heparin-associated thrombocytopenia: Isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen
16. Heparin-induced thrombocytopenia: Towards consensus
17. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety
18. Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia
19. Limitations of conventional treatment options for heparin-induced thrombocytopenia
20. Efficacy and safety of early versus late initiation of warfarin during heparin therapy in acute thromboembolism